Show simple item record

dc.contributor.authorLin, Kuan-Hung
dc.contributor.authorAli, Akbar
dc.contributor.authorRusere, Linah
dc.contributor.authorSoumana, Djade I.
dc.contributor.authorYilmaz, Nese Kurt
dc.contributor.authorSchiffer, Celia A.
dc.date2022-08-11T08:08:21.000
dc.date.accessioned2022-08-23T15:52:19Z
dc.date.available2022-08-23T15:52:19Z
dc.date.issued2017-04-28
dc.date.submitted2017-06-23
dc.identifier.citationJ Virol. 2017 Apr 28;91(10). pii: e00045-17. doi: 10.1128/JVI.00045-17. Print 2017 May 15. <a href="https://doi.org/10.1128/JVI.00045-17">Link to article on publisher's site</a>
dc.identifier.issn0022-538X (Linking)
dc.identifier.doi10.1128/JVI.00045-17
dc.identifier.pmid28298600
dc.identifier.urihttp://hdl.handle.net/20.500.14038/29110
dc.description.abstractThe mosquito-transmitted dengue virus (DENV) infects millions of people in tropical and subtropical regions. Maturation of DENV particles requires proper cleavage of the viral polyprotein, including processing of 8 of the 13 substrate cleavage sites by dengue virus NS2B/NS3 protease. With no available direct-acting antiviral targeting DENV, NS2/NS3 protease is a promising target for inhibitor design. Current design efforts focus on the nonprime side of the DENV protease active site, resulting in highly hydrophilic and nonspecific scaffolds. However, the prime side also significantly modulates DENV protease binding affinity, as revealed by engineering the binding loop of aprotinin, a small protein with high affinity for DENV protease. In this study, we designed a series of cyclic peptides interacting with both sides of the active site as inhibitors of dengue virus protease. The design was based on two aprotinin loops and aimed to leverage both key specific interactions of substrate sequences and the entropic advantage driving aprotinin's high affinity. By optimizing the cyclization linker, length, and amino acid sequence, the tightest cyclic peptide achieved a Ki value of 2.9 muM against DENV3 wild-type (WT) protease. These inhibitors provide proof of concept that both sides of DENV protease active site can be exploited to potentially achieve specificity and lower hydrophilicity in the design of inhibitors targeting DENV. IMPORTANCE: Viruses of the flaviviral family, including DENV and Zika virus transmitted by Aedes aegypti, continue to be a threat to global health by causing major outbreaks in tropical and subtropical regions, with no available direct-acting antivirals for treatment. A better understanding of the molecular requirements for the design of potent and specific inhibitors against flaviviral proteins will contribute to the development of targeted therapies for infections by these viruses. The cyclic peptides reported here as DENV protease inhibitors provide novel scaffolds that enable exploiting the prime side of the protease active site, with the aim of achieving better specificity and lower hydrophilicity than those of current scaffolds in the design of antiflaviviral inhibitors.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=28298600&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsPublisher PDF posted as allowed by the publisher's author rights policy at http://journals.asm.org/site/misc/ASM_Author_Statement.xhtml.
dc.subjectZika
dc.subjectantimicrobial peptides
dc.subjectantiviral agents
dc.subjectdengue fever
dc.subjectdrug design
dc.subjectprotease inhibitors
dc.subjectreceptor-ligand interaction
dc.subjectstructural biology
dc.subjectsubstrate
dc.subjectBiochemistry
dc.subjectEnzymes and Coenzymes
dc.subjectMedicinal and Pharmaceutical Chemistry
dc.subjectMedicinal-Pharmaceutical Chemistry
dc.subjectStructural Biology
dc.subjectVirology
dc.subjectVirus Diseases
dc.titleDengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side
dc.typeJournal Article
dc.source.journaltitleJournal of virology
dc.source.volume91
dc.source.issue10
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=2340&amp;context=faculty_pubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/1337
dc.identifier.contextkey10343917
refterms.dateFOA2022-08-23T15:52:19Z
html.description.abstract<p>The mosquito-transmitted dengue virus (DENV) infects millions of people in tropical and subtropical regions. Maturation of DENV particles requires proper cleavage of the viral polyprotein, including processing of 8 of the 13 substrate cleavage sites by dengue virus NS2B/NS3 protease. With no available direct-acting antiviral targeting DENV, NS2/NS3 protease is a promising target for inhibitor design. Current design efforts focus on the nonprime side of the DENV protease active site, resulting in highly hydrophilic and nonspecific scaffolds. However, the prime side also significantly modulates DENV protease binding affinity, as revealed by engineering the binding loop of aprotinin, a small protein with high affinity for DENV protease. In this study, we designed a series of cyclic peptides interacting with both sides of the active site as inhibitors of dengue virus protease. The design was based on two aprotinin loops and aimed to leverage both key specific interactions of substrate sequences and the entropic advantage driving aprotinin's high affinity. By optimizing the cyclization linker, length, and amino acid sequence, the tightest cyclic peptide achieved a Ki value of 2.9 muM against DENV3 wild-type (WT) protease. These inhibitors provide proof of concept that both sides of DENV protease active site can be exploited to potentially achieve specificity and lower hydrophilicity in the design of inhibitors targeting DENV.</p> <p>IMPORTANCE: Viruses of the flaviviral family, including DENV and Zika virus transmitted by Aedes aegypti, continue to be a threat to global health by causing major outbreaks in tropical and subtropical regions, with no available direct-acting antivirals for treatment. A better understanding of the molecular requirements for the design of potent and specific inhibitors against flaviviral proteins will contribute to the development of targeted therapies for infections by these viruses. The cyclic peptides reported here as DENV protease inhibitors provide novel scaffolds that enable exploiting the prime side of the protease active site, with the aim of achieving better specificity and lower hydrophilicity than those of current scaffolds in the design of antiflaviviral inhibitors.</p>
dc.identifier.submissionpathfaculty_pubs/1337
dc.contributor.departmentSchiffer Lab
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.source.pagese00045-17


Files in this item

Thumbnail
Name:
e00045_17.full.pdf
Size:
1.094Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record